Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Altimmune, Inc. (ALT)

4.32   0.13 (3.1%) 03-24 16:00
Open: 4.23 Pre. Close: 4.19
High: 4.43 Low: 4.19
Volume: 3,666,821 Market Cap: 213(M)

Technical analysis

as of: 2023-03-24 4:23:56 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 11.01     One year: 14.83
Support: Support1: 4.13    Support2: 3.44
Resistance: Resistance1: 9.43    Resistance2: 12.69
Pivot: 9.23
Moving Average: MA(5): 5.71     MA(20): 9.9
MA(100): 11.99     MA(250): 11.12
MACD: MACD(12,26): -2     Signal(9): -1.2
Stochastic oscillator: %K(14,3): 1.1     %D(3): 4.5
RSI: RSI(14): 17.6
52-week: High: 23.48  Low: 3.82
Average Vol(K): 3-Month: 1,773 (K)  10-Days: 4,506 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALT ] has closed above bottom band by 8.0%. Bollinger Bands are 177.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.44 - 4.47 4.47 - 4.5
Low: 4.12 - 4.16 4.16 - 4.19
Close: 4.26 - 4.32 4.32 - 4.37

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Headline News

Wed, 22 Mar 2023
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data - Nasdaq

Tue, 21 Mar 2023
Altimmune Inc. (ALT stock) - Bad Drug Trial News Weighs it Down - The Coin Republic

Tue, 21 Mar 2023
Healthcare Stocks Moving Tuesday: QNCX, DRMA, IBRX, NCNA, ALT, CHEK, ROIVW, ATNX - InvestorsObserver

Tue, 21 Mar 2023
Altimmune's obesity drug safety concerns shrink shares -

Tue, 14 Mar 2023
Q1 2023 EPS Estimates for Altimmune, Inc. (NASDAQ:ALT) Analyst's ... - Best Stocks

Tue, 14 Mar 2023
Two Sigma Advisers LP Raises Stock Position in Altimmune, Inc ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 49 (M)
% Held by Insiders 3.959e+007 (%)
% Held by Institutions 0.8 (%)
Shares Short 6,170 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.761e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 128
Return on Assets (ttm) 902.9
Return on Equity (ttm) -25.8
Qtrly Rev. Growth -68000
Gross Profit (p.s.) 0
Sales Per Share -489.67
EBITDA (p.s.) -7.83556e+008
Qtrly Earnings Growth -1.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -63 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.1

Stock Dividends

Dividend 0
Forward Dividend 6.38e+006
Dividend Yield 0%
Dividend Pay Date 2018-09-13
Ex-Dividend Date 2017-01-19
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.